Human IFN-alpha / beta R2 Antibody

Catalog #: MAB4015
3 Citations Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB4015-100
MAB4015-SP

IFN-beta Inhibition of EMCV-induced Cytopathy and Neutralization by Human IFN-alpha / beta R2 Antibody.

1 Image

Product Details

Citations (3)

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human IFN-alpha / beta R2 Antibody Summary

Species Reactivity

Human

Specificity

Detects human IFN‑ alpha / beta R2 in direct ELISAs.

Source

Monoclonal Mouse IgG_2B Clone # 493715

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Mouse myeloma cell line, NS0-derived recombinant human IFN‑ alpha / beta R2
Ile27-Lys243
Accession # P48551

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Neutralization

Measured by its ability to neutralize IFN‑ beta inhibition of EMCV-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line. The Neutralization Dose (ND₅₀) is typically 4-20 µg/mL in the presence of 30 pg/mL Recombinant Human IFN‑ beta.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

IFN-beta Inhibition of EMCV-induced Cytopathy and Neutralization by Human IFN-alpha / beta R2 Antibody. Recombinant Human IFN-beta (Catalog # 8499-IF) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Human IFN-beta (30 pg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IFN-a/ beta R2 Monoclonal Antibody (Catalog # MAB4015). The ND₅₀ is typically 4-20 µg/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IFN-alpha/beta R2

IFN-alpha / beta R2, also known as IFNAR2, is a 100 kDa glycoprotein in the class II cytokine receptor family. These proteins form heterodimeric receptor complexes that transduce signals from the interferon, IL-10, and IL-28 families of cytokines (1, 2). IFN-alpha / beta R2, in association with IFN-alpha / beta R1, is required for mediating the antiviral, antiproliferative, and apoptotic effects of the type I interferons IFN-alpha and IFN-beta. IFN-alpha / beta R2 is the principal ligand binding subunit of the receptor. Ligand binding is stabilized by the subsequent association with IFN-alpha / beta R1, resulting in the formation of a signaling ternary receptor complex (3, 4). Mature human IFN-alpha / beta R2 consists of a 217 amino acid (aa) extracellular domain (ECD) with two fibronectin type III repeats, a 21 aa transmembrane segment, and a 251 aa cytoplasmic domain. Alternate splicing generates a secreted isoform that corresponds to the ECD and a 50 kDa transmembrane isoform with a substituted and truncated cytoplasmic region (5, 6). The short isoform is impaired in its ability to activate signaling molecules and functions as a dominant negative receptor subunit (7-9). IFN-alpha / beta R2 is also subject to presenilin-dependent intramembrane proteolysis, resulting in the liberation of nearly the entire ECD as well as the cytoplasmic domain which migrates to the nucleus and can inhibit gene transcription (10). High concentrations of soluble IFN-alpha / beta R2 bind and neutralize IFN-alpha and IFN-beta, while lower concentrations prolong the antiviral activity of circulating IFN-beta but not IFN-alpha (11). Human but not mouse IFN-alpha / beta R2 constitutively associates with STAT4, which may account for species specific differences observed in type I interferon responses (12). Within the ECD, human IFN-alpha / beta R2 shares 63%, 60%, and 48% aa sequence identity with bovine, mouse, and ovine IFN-alpha / beta R2, respectively.

References

Langer, J.A. et al. (2004) Cytokine Growth Factor Rev. 15:33.
Pestka, S. et al. (2004) Immunol. Rev. 202:8.
Lamken, P. et al. (2004) J. Mol. Biol. 341:303.
Arduini, R.M. et al. (1999) Prot. Sci. 8:1867.
Lutfalla, G. et al. (1995) EMBO J. 14:5100.
Novick, D. et al. (1995) J. Leukocyte Biol. 57:712.
Pfeffer, L.M. et al. (1997) J. Biol. Chem. 272:11002.
Gazziola, C. et al. (2005) Int. J. Oncol. 26:129.
Kotenko, S.V. and S. Pestka (2000) Oncogene 19:2557.
Saleh, A.Z.M. et al. (2004) Oncogene 23:7076.
McKenna, S.D. et al. (2004) J. Interferon Cytokine Res. 24:119.
Tyler, D.R. et al. (2007) Mol. Immunol. 44:1864.

Long Name

Interferon alpha/beta Receptor 2

Entrez Gene IDs

3455 (Human); 15976 (Mouse); 102140083 (Cynomolgus Monkey)

Alternate Names

beta receptor10; human interferon alpha; human interferon alpha/beta receptor; IFNABR; IFN-alpha binding protein; IFN-alpha/beta R2; IFN-alpha/beta receptor 2; IFN-alpha-REC; IFNAR2; IFN-aR2; IFNARB; IFNbR2; IFN-bR2; IFN-R; IFN-R-2; interferon (alpha, beta and omega) receptor 2; Interferon alpha binding protein; interferon alpha/beta receptor 2; interferon-alpha/beta receptor beta chain; Type I interferon receptor 2

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Human IFN-alpha / beta R2 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

3 Citations: Showing 1 - 3
Filter your results:

Filter by:

Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer
Authors: Baosheng Chen, David M. Alvarado, Micah Iticovici, Nathan S. Kau, Haeseong Park, Parag J. Parikh et al.
Cancer Immunology Research
Lysine catabolism reprograms tumour immunity through histone crotonylation
Authors: Yuan, H;Wu, X;Wu, Q;Chatoff, A;Megill, E;Gao, J;Huang, T;Duan, T;Yang, K;Jin, C;Yuan, F;Wang, S;Zhao, L;Zinn, PO;Abdullah, KG;Zhao, Y;Snyder, NW;Rich, JN;
Nature
Species: Human, Transgenic Mouse, Xenograft
Sample Types: Whole Cells, In Vivo
Applications: Neutralization
A human iPSC-array-based GWAS identifies a virus susceptibility locus in the NDUFA4 gene and functional variants
Authors: Y Han, L Tan, T Zhou, L Yang, L Carrau, LA Lacko, M Saeed, J Zhu, Z Zhao, BE Nilsson-Pa, FT Lira Neto, C Cahir, AM Giani, JC Chai, Y Li, X Dong, D Moroziewic, NYSCF Glob, D Paull, T Zhang, S Koo, C Tan, R Danziger, Q Ba, L Feng, Z Chen, A Zhong, GJ Wise, JZ Xiang, H Wang, RE Schwartz, BR tenOever, SA Noggle, CM Rice, Q Qi, T Evans, S Chen
Cell Stem Cell, 2022-10-06;29(10):1475-1490.e6.
Species: Human
Sample Types: Whole Cells
Applications: ICC